Article thumbnail

Vaccination Against Hepatitis B Virus (HBV) in HIV-1-Infected Patients With Isolated Anti-HBV Core Antibody: The ANRS HB EP03 CISOVAC Prospective Study.

By Lionel Piroth, Odile Launay, Marie-Louise Michel, Abderrahmane Bourredjem, Patrick Miailhes, Faiza Ajana, Catherine Chirouze, David Zucman, Marie-Josee Wendling, Dani Nazzal, Fabrice Carrat, David Rey and Christine Binquet


International audience Although an isolated anti-hepatitis B virus (HBV) core antibody (anti-HBc) serological profile is frequent in human immunodeficiency virus (HIV)-infected patients, data on HBV vaccination in these patients are scarce.  A prospective multicenter study was conducted to assess the immunogenicity of HBV vaccination in 54 patients with an isolated anti-HBc profile and undetectable HIV load. They were vaccinated with 1 dose (20 µg) of recombinant HBV vaccine. Those with an anti-HBV surface antibody (anti-HBs) level of 100 mIU/mL 4 weeks after a single recall dose of HBV vaccine should be further vaccinated with a reinforced triple double-dose scheme

Topics: [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology
Publisher: 'Oxford University Press (OUP)'
Year: 2016
OAI identifier: oai:HAL:hal-01309269v1
Provided by: HAL-HCL
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://hal.archives-ouvertes.... (external link)
  • https://hal.archives-ouvertes.... (external link)
  • https://hal.archives-ouvertes.... (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.